PGEN
Precigen Inc
NASDAQ · Biotechnology
$4.29
+0.05 (+1.18%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 5.20M | 8.00M | 395.97M | 411.38M | 421.12M |
| Net Income | -166,828,240 | -231,028,490 | -29,622,139 | -34,816,902 | -35,997,358 |
| EPS | — | — | — | — | — |
| Profit Margin | -3,216.2% | -3,055.4% | -7.5% | -8.5% | -8.6% |
| Rev Growth | -35.0% | -35.0% | +6.2% | +17.8% | -9.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 710.80M | 657.59M | 697.63M |
| Total Equity | — | — | 701.90M | 694.85M | 748.63M |
| D/E Ratio | — | — | 1.01 | 0.95 | 0.93 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -165,094,500 | -241,329,089 | -51,308,756 | -49,679,638 | -48,292,540 |
| Free Cash Flow | — | — | -33,088,570 | -21,385,787 | -28,685,035 |